Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related Searches

Epidemiology, prevention, and control of malaria in endemic areas

INTRODUCTION

Malaria is endemic throughout most of the tropics. Of the approximately 3.4 billion people worldwide who are exposed annually, 1.2 billion are at high risk; the World Health Organization (WHO) states that more than 207 million developed symptomatic malaria in 2012 [1]. Between 2000 and 2010, the number of reported annual malaria cases in 34 malaria-eliminating countries decreased by 85 percent from 1.5 million to 232,000 cases [2]. Most of these are attributable to P. falciparum, but P. vivax and P. knowlesi can also cause severe disease. Malaria deaths peaked at 1.82 million in 2004 and fell to 1.24 million in 2010 (714,000 children <5 years and 524,000 individuals ≥5 years); over 80 percent of the deaths occur in sub-Saharan Africa [3]. The WHO’s estimates of deaths from malaria (627,000 in 2012; uncertainty range 473,000 to 789,000) are approximately half the more reliable estimates above.

Important components for reducing the burden of malaria morbidity and mortality include more sensitive diagnostic tools, effective use of antimalarial drugs, and improved personal protection and mosquito control. The approach to elimination or control of malaria includes these basics, along with improvements in tracking of human illness and parasite surveillance, and effective resource delivery.

Issues related to epidemiology of malaria, including definitions and strategies for control, will be reviewed. Other related topics are discussed in detail separately. (See related topics.)

EPIDEMIOLOGY

Malaria is transmitted via the bite of a female Anopheles spp mosquito, which occurs mainly between dusk and dawn. Other comparatively rare mechanisms for transmission include: congenitally acquired disease, blood transfusion, sharing of contaminated needles, and organ transplantation [4,5].

Malaria occurs throughout most of the tropical regions of the world, with P. falciparum causing the largest burden of disease, followed by P. vivax (figure 1) [6]. P. falciparum predominates in Africa, New Guinea, and Hispaniola (Haiti and the Dominican Republic); P. vivax is more common in the Americas and the western Pacific. The prevalence of these two species is approximately equal in the Indian subcontinent, eastern Asia, and Oceania (table 1) [7-9]. P. malariae is uncommon and is found in most endemic areas, especially in sub-Saharan Africa. P. ovale, even less common, is relatively unusual outside of Africa and, where it is found, comprises <1 percent of isolates. P. knowlesi, similar morphologically to P. malariae, has been identified by molecular methods in patients in Malaysia, the Philippines, Thailand, and Myanmar [10]; this species has not yet been proven to be transmitted from humans to mosquitoes (ie, a monkey reservoir may be required to infect mosquitoes).

                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Apr 3, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. WHO. World Malaria Report, 2013. Geneva, Switzerland http://www.who.int/malaria/world_malaria_report_2013/en/ (Accessed on April 3, 2014)
  2. WHO. World malaria report 2011. Geneva: World Health Organization, 2011.
  3. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413.
  4. Filler S, Causer LM, Newman RD, et al. Malaria surveillance--United States, 2001. MMWR Surveill Summ 2003; 52:1.
  5. Owusu-Ofori AK, Betson M, Parry CM, et al. Transfusion-transmitted malaria in Ghana. Clin Infect Dis 2013; 56:1735.
  6. Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38.
  7. Snow RW, Guerra CA, Noor AM, et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214.
  8. Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:79.
  9. Breman JG. Eradicating malaria. Sci Prog 2009; 92:1.
  10. White NJ. Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis 2008; 46:172.
  11. Smith T, Maire N, Dietz K, et al. Relationship between the entomologic inoculation rate and the force of infection for Plasmodium falciparum malaria. Am J Trop Med Hyg 2006; 75:11.
  12. Kiszewski AE, Teklehaimanot A. A review of the clinical and epidemiologic burdens of epidemic malaria. Am J Trop Med Hyg 2004; 71:128.
  13. WHO Global Malaria Control and Elimination: report of a technical review 17-18 January 2008. Geneva, pp. 1-47.
  14. Bruce Chwatt LJ. Essential Malariology, Wiley Medical, 1985. p.193.
  15. Laufer MK, Takala-Harrison S, Dzinjalamala FK, et al. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 2010; 202:801.
  16. World Bank, Millennium Development Goals, 2005.
  17. Teklehaimanot A, Singer B, Spielman A, et al. UN Millennium Project. Coming to grips with malaria in the new millennium. Task Force on HIV/AIDS, malaria, TB, and access to essential medicines. Working Group on Malaria, 2005, p. 10.
  18. Skarbinski J, Ouma PO, Causer LM, et al. Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial. Am J Trop Med Hyg 2009; 80:919.
  19. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001; 64:1.
  20. WHO, World Malaria Report, 2008. Geneva, Switzerland.
  21. WHO, Chemotherapy of malaria, 2006.
  22. Crawley J, Sismanidis C, Goodman T, et al. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. Lancet 2012; 380:1001.
  23. Aponte JJ, Schellenberg D, Egan A, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009; 374:1533.
  24. Gosling RD, Gesase S, Mosha JF, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1521.
  25. Benn CS, Aaby P. Does IPTi decrease malaria morbidity but not mortality? Lancet 2012; 380:958.
  26. Pearce RJ, Ord R, Kaur H, et al. A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania. J Infect Dis 2013; 207:848.
  27. WHO. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy, Geneva: WHO 2009:1-11. http://www.who.int/malaria/publications/atoz/tegconsultiptiapr2009report.pdf (Accessed on March 13, 2013).
  28. Meremikwu MM, Donegan S, Sinclair D, et al. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev 2012; 2:CD003756.
  29. Hamon J. Les moustiques anthropophiles de la région de Bobo Dioulasso: cycles d'aggressivité et variations saisonnières. Annales de la Societé d'Entomologie de la France 1963; 132:85.
  30. Pates H, Curtis C. Mosquito behavior and vector control. Annu Rev Entomol 2005; 50:53.
  31. Curtis CF, Maxwell CA, Magesa SM, et al. Insecticide-treated bed-nets for malaria mosquito control. J Am Mosq Control Assoc 2006; 22:501.
  32. Velema JP. Malaria, bednets, and mortality. Lancet 1991; 338:642.
  33. Wang D, Kamijima M, Imai R, et al. Biological monitoring of pyrethroid exposure of pest control workers in Japan. J Occup Health 2007; 49:509.
  34. Lengeler C. Insecticide Treated Bednets and Curtains for Malaria Control: A Cochrane Review. The Cochrane Library. Issue 3, 2005. Oxford Update Software Ltd.
  35. Zaim M, Aitio A, Nakashima N. Safety of pyrethroid-treated mosquito nets. Med Vet Entomol 2000; 14:1.
  36. Lindblade KA, Eisele TP, Gimnig JE, et al. Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up. JAMA 2004; 291:2571.
  37. Askjaer N, Maxwell C, Chambo W, et al. Insecticide-treated bed nets reduce plasma antibody levels and limit the repertoire of antibodies to Plasmodium falciparum variant surface antigens. Clin Diagn Lab Immunol 2001; 8:1289.
  38. Henry MC, Assi SB, Rogier C, et al. Protective efficacy of lambda-cyhalothrin treated nets in Anopheles gambiae pyrethroid resistance areas of Côte d'Ivoire. Am J Trop Med Hyg 2005; 73:859.
  39. Trape JF, Tall A, Diagne N, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011; 11:925.
  40. Asidi A, N'Guessan R, Akogbeto M, et al. Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, benin. Emerg Infect Dis 2012; 18:1101.
  41. Curtis CF, Maxwell CA, Finch RJ, Njunwa KJ. A comparison of use of a pyrethroid either for house spraying or for bednet treatment against malaria vectors. Trop Med Int Health 1998; 3:619.
  42. World Health Organization. Manual for indoor residual spraying application of residual sprays for vector control. WHO/CDS/WHOPES/GCDPP/2000.3 Rev.1.
  43. Sadasivaiah S, Tozan Y, Breman JG. Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control? Am J Trop Med Hyg 2007; 77:249.
  44. Roberts DR, Alecrim WD. Behavioral response of Anopheles darlingi to DDT-sprayed house walls in Amazonia. Bull Pan Am Health Organ 1991; 25:210.
  45. MacDonald G. Epidemiology and Control of Malaria, Oxford University Press, London 1957.
  46. Stockholm Convention on Persistent Organic Pollutants. http://chm.pops.int/ (Accessed on September 01, 2009).
  47. Giglioli G. Changes in the pattern of mortality following the eradication of hyperendemic malaria from a highly susceptible community. Bull World Health Organ 1972; 46:181.
  48. Maharaj R, Mthembu DJ, Sharp BL. Impact of DDT re-introduction on malaria transmission in KwaZulu-Natal. S Afr Med J 2005; 95:871.
  49. Curtis CF. Integrated vector management for malaria. In: Integrated Pest Management, Radcliffe E (Ed), Cambridge University Press, Cambridge 2008.
  50. Ghosh SK, Tiwari SN, Sathyanarayan TS, et al. Larvivorous fish in wells target the malaria vector sibling species of the Anopheles culicifacies complex in villages in Karnataka, India. Trans R Soc Trop Med Hyg 2005; 99:101.
  51. Yapabandara AM, Curtis CF, Wickramasinghe MB, Fernando WP. Control of malaria vectors with the insect growth regulator pyriproxyfen in a gem-mining area in Sri Lanka. Acta Trop 2001; 80:265.
  52. Fillinger U, Lindsay SW. Suppression of exposure to malaria vectors by an order of magnitude using microbial larvicides in rural Kenya. Trop Med Int Health 2006; 11:1629.
  53. Andreasen MH, Curtis CF. Optimal life stage for radiation sterilization of Anopheles males and their fitness for release. Med Vet Entomol 2005; 19:238.
  54. Klassen W, Curtis CF. History of the Sterile Insect Technique (SIT). In: The Sterile Insect Technique: Principles and Practice in Area-wide Integrated Pest Management, Dyck VA, Hendrichs L, Robinson AS (Eds), Springer, Heidelberg, Germany 2005. p.3.
  55. Catteruccia F, Benton JP, Crisanti A. An Anopheles transgenic sexing strain for vector control. Nat Biotechnol 2005; 23:1414.
  56. Ito J, Ghosh A, Moreira LA, et al. Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite. Nature 2002; 417:452.
  57. Chen CH, Huang H, Ward CM, et al. A synthetic maternal-effect selfish genetic element drives population replacement in Drosophila. Science 2007; 316:597.
  58. Burt A, Trivers R. Genes in Conflict, Belknap Press, Harvard University, 2006.
  59. Curtis CF, Coleman PG, Kelly D. Advantages and limitations of transgenic vector control: sterile males versus gene drivers. In: Genetically Modified Mosquitoes for Malaria Control, Boete C (Ed), Landes Bioscience, Georgetown, Texas 2006. p.60.
  60. Rowland M, Mohammed N, Rehman H, et al. Anopheline vectors and malaria transmission in eastern Afghanistan. Trans R Soc Trop Med Hyg 2002; 96:620.
  61. Van Bortel W, Trung HD, Thuan le K, et al. The insecticide resistance status of malaria vectors in the Mekong region. Malar J 2008; 7:102.
  62. Chandre F, Darrier F, Manga L, et al. Status of pyrethroid resistance in Anopheles gambiae sensu lato. Bull World Health Organ 1999; 77:230.
  63. Debboun M, Frances SP, Strickman D. Insect Repellents, CRC Press, Boca Raton 2007.
  64. Hill N, Lenglet A, Arnéz AM, Carneiro I. Plant based insect repellent and insecticide treated bed nets to protect against malaria in areas of early evening biting vectors: double blind randomised placebo controlled clinical trial in the Bolivian Amazon. BMJ 2007; 335:1023.
  65. Rowland M, Downey G, Rab A, et al. DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan. Trop Med Int Health 2004; 9:335.
  66. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521.
  67. Agnandji ST, Asante KP, Lyimo J, et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010; 202:1076.
  68. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863.
  69. RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284.
  70. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111.
  71. Bejon P, White MT, Olotu A, et al. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis 2013; 13:319.
  72. Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008; 359:2533.
  73. Breman JG, Plowe CV. A malaria vaccine for control: more progress. J Infect Dis 2009; 200:317.
  74. http://www.who.int/maternal_child_adolescent/documents/iron_statement/en/ (Accessed on September 17, 2013).
  75. Zlotkin S, Newton S, Aimone AM, et al. Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial. JAMA 2013; 310:938.
  76. Sturrock HJ, Novotny JM, Kunene S, et al. Reactive case detection for malaria elimination: real-life experience from an ongoing program in Swaziland. PLoS One 2013; 8:e63830.
  77. Breman JG, Holloway CN. Malaria surveillance counts. Am J Trop Med Hyg 2007; 77:36.
  78. Noor AM, Kinyoki DK, Mundia CW, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet 2014.
  79. Greenwood B, Koram K. Malaria control in Africa: progress but still much to do. Lancet 2014.
  80. Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12:488.